Details of Drug

Drug General Information (ID: D1222)
Drug Name	Pantoprazole
Drug Type	Small molecule
Drug Synonymous	Astropan; Pantoprazol; Pantoprazolum; Pantoprozole; Pantor; Pantozol; Protium; Protonix; Somac; Pantoprazole Na; Pantoprazole Sodium; Protonix IV; BY 1023; Astropan (TN); BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; Pantor (TN); Pantotab (TN); Pantozol (TN); Protium (TN); Protonix (TN); SK&F 96022; SK-96022; SKF-96022; Somac (TN); Ulcepraz (TN); Pantoprazole (USAN/INN); Pantoprazole [USAN:BAN:INN]; SK&F-96022; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole Click to Show/Hide
Disease Class	DA22: Gastro-oesophageal reflux disease
Therapeutic Class	Antiulcer Agents
Structure
Structure	3D Structure		2D Structure
Formula	C16H15F2N3O4S
InChI	1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
InChIKey	IQPSEEYGBUAQFF-UHFFFAOYSA-N
Canonical SMILES	COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
External Link
	Pubchem ID	4679
	CAS Number	102625-70-7
	CHEBI ID	7915
	TTD ID	D0T6XX
	VARIDT ID	DR00458

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects BM005 Altered gastric pH BM010 Transporter inhibition BM011 Transporter induction BM012 Competitive inhibition of transporters BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM024 Competitive inhibition of metabolic enzyme BM028 Competitive inhibition of renal tubular secretion BM066 Increased risk of hypomagnesemia BM075 Increased risk of photosensitivity reactions BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Pantoprazole
Affected gastrointestinal absorption
	Altered gastric pH					Drug Num: 53
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0008		Acalabrutinib	C26H23N7O2	71226662	Major		Inter Info	[1]
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[2], [3], [4], [5], [6], [7], [8], [9]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Major		Inter Info	[4], [10]
D0428		Dasatinib	C22H26ClN7O2S	3062316	Major		Inter Info	[11]
D0595		Erlotinib	C22H23N3O4	176870	Major		Inter Info	[3], [4], [12], [13]
D1119		Nelfinavir	C32H45N3O4S	64143	Major		Inter Info	[16], [9]
D1124		Neratinib	C30H29ClN6O3	9915743	Major		Inter Info	[3], [17]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[4], [18], [19], [20], [21], [22]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[23]
D1404		Rilpivirine	C22H18N6	6451164	Major		Inter Info	[24]
D1459		Selpercatinib	C29H31N7O3	134436906	Major		Inter Info	[4], [25]
D1686		Velpatasvir	C49H54N8O8	67683363	Major		Inter Info	[4], [26]
D0141		Bacampicillin	C21H27N3O7S	441397	Moderate		Inter Info	[59], [60]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[61]
D0278		Cefditoren	C19H18N6O5S3	9870843	Moderate		Inter Info	[62]
D0288		Cefpodoxime	C15H17N5O6S2	6335986	Moderate		Inter Info	[59], [63], [64], [60]
D0297		Cefuroxime	C16H16N4O8S	5479529	Moderate		Inter Info	[59], [63], [64], [60]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Moderate		Inter Info	[66]
D0439		Delavirdine	C22H28N6O3S	5625	Moderate		Inter Info	[82]
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[83], [84], [85], [86], [29], [87], [31], [32], [33], [34], [27]
D0649		Ferrous fumarate	C4H2FeO4	6433164	Moderate		Inter Info	[94], [95], [29], [87], [31], [32], [33], [34], [96], [97]
D0650		Ferrous gluconate	C12H22FeO14	23616740	Moderate		Inter Info	[94], [95], [29], [87], [31], [32], [33], [34], [96], [97]
D0651		Ferrous sulfate anhydrous	FeO4S	24393	Moderate		Inter Info	[94], [87], [98]
D0692		Fosamprenavir	C25H36N3O9PS	131536	Moderate		Inter Info	[100]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[102]
D0799		Indinavir	C36H47N5O4	5362440	Moderate		Inter Info	[104]
D0847		Iron	Fe	23925	Moderate		Inter Info	[94], [87], [98]
D0849		Iron protein succinylate	NA	NA	Moderate		Inter Info	[94], [95], [29], [87], [31], [32], [33], [34], [96], [97]
D0867		Itraconazole	C35H38Cl2N8O4	55283	Moderate		Inter Info	[105], [106], [107], [108], [109], [29], [87], [31], [32], [33], [34], [110]
D0880		Ketoconazole	C26H28Cl2N4O4	456201	Moderate		Inter Info	[105], [106], [107], [108], [109], [29], [87], [31], [32], [33], [34], [110]
D0898		Ledipasvir	C49H54F2N8O6	67505836	Moderate		Inter Info	[3], [4], [112]
D0925		Levothyroxine	C15H11I4NO4	5819	Moderate		Inter Info	[3], [4], [114]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[3], [4], [114]
D0935		Liotrix	C30H21I7N2Na2O8	71371	Moderate		Inter Info	[3], [4], [114]
D1094		Mycophenolate mofetil	C23H31NO7	5281078	Moderate		Inter Info	[119], [120]
D1109		Naproxen	C14H14O3	156391	Moderate		Inter Info	[121]
D1315		Posaconazole	C37H42F2N8O4	468595	Moderate		Inter Info	[127], [128], [129], [130], [131], [132], [133], [134], [135], [136]
D1408		Riociguat	C20H19FN8O2	11304743	Moderate		Inter Info	[139]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[3], [4], [114]
D0395		Cyanocobalamin	C63H88CoN14O14P	5311498	Minor		Inter Info	[158], [159], [160], [161], [162]
D0017		Acetylsalicylic acid	C9H8O4	2244	Minor		Inter Info	[163], [164], [165]
D0133		Axitinib	C22H18N4OS	6450551	Minor		Inter Info	[166]
D0331		Choline salicylate	C12H19NO4	54686350	Minor		Inter Info	[163], [164], [165]
D0539		Duloxetine	C18H19NOS	60835	Minor		Inter Info	[168]
D0989		Mecobalamin	C63H91CoN13O14P	10898559	Minor		Inter Info	[159], [160], [162]
D1272		Phenyl salicylate	C13H10O3	8361	Minor		Inter Info	[163], [164], [165]
D1313		Ponatinib	C29H27F3N6O	24826799	Minor		Inter Info	[3], [171]
D1328		Prasugrel	C20H20FNO3S	6918456	Minor		Inter Info	[172], [79]
D1377		Raltegravir	C20H21FN6O5	54671008	Minor		Inter Info	[173]
D1439		Salicylic acid (sodium)	C7H6O3	338	Minor		Inter Info	[163], [164], [165]
D1442		Salsalate	C14H10O5	5161	Minor		Inter Info	[163], [164], [165]
D1681		Vandetanib	C22H24BrFN4O2	3081361	Minor		Inter Info	[3], [4], [18], [174]
D1701		Vismodegib	C19H14Cl2N2O3S	24776445	Minor		Inter Info	[3], [4], [175]
Affected cellular transport
	Transporter inhibition					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0699		Fostamatinib	C23H26FN6O9P	11671467	Moderate		Inter Info	[101]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 23
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0667		Fluconazole	C13H12F2N6O	3365	Moderate		Inter Info	[4], [28], [29], [30], [31], [32], [33], [34], [35], [36]
D0687		Fluvoxamine	C15H21F3N2O2	5324346	Moderate		Inter Info	[37], [29], [31], [32], [33], [34], [38]
D0002		Abametapir (topical)	C12H12N2	15664	Moderate		Inter Info	[39]
D0087		Anisindione	C16H12O3	2197	Moderate		Inter Info	[42], [43], [29], [44], [30], [31], [45], [32], [34], [46], [47], [48], [49], [50], [51]
D0106		Armodafinil	C15H15NO2S	9690109	Moderate		Inter Info	[3], [52], [53], [54], [55]
D0300		Cenobamate	C10H10ClN5O2	11962412	Moderate		Inter Info	[65]
D0364		Clopidogrel	C16H16ClNO2S	60606	Moderate		Inter Info	[67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [34], [78], [79], [80], [81]
D0481		Dicoumarol	C19H12O6	54676038	Moderate		Inter Info	[45], [49], [51]
D0543		Duvelisib	C22H17ClN6O	50905713	Moderate		Inter Info	[88]
D0628		Etravirine	C20H15BrN6O	193962	Moderate		Inter Info	[91]
D0638		Fedratinib	C27H36N6O3S	16722836	Moderate		Inter Info	[4], [92]
D0642		Fenofibrate	C20H21ClO4	3339	Moderate		Inter Info	[3], [4], [93]
D0665		Flibanserin	C20H21F3N4O	6918248	Moderate		Inter Info	[99]
D0732		Glycerol phenylbutyrate	C33H38O6	10482134	Moderate		Inter Info	[4], [103]
D0896		Larotrectinib	C21H22F2N6O2	46188928	Moderate		Inter Info	[3], [4], [111]
D0946		Lonafarnib	C27H31Br2ClN4O2	148195	Moderate		Inter Info	[115]
D1081		Modafinil	C15H15NO2S	4236	Moderate		Inter Info	[3], [52], [53], [54], [55]
D1189		Osilodrostat	C13H10FN3	44139752	Moderate		Inter Info	[123]
D1198		Oxcarbazepine	C15H12N2O2	34312	Moderate		Inter Info	[3], [124]
D1706		Voriconazole	C16H14F3N5O	71616	Moderate		Inter Info	[153], [154], [29], [30], [31], [32], [33], [34], [155], [156]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[42], [43], [29], [44], [30], [31], [45], [32], [34], [46], [47], [48], [49], [50], [51]
D0193		Bortezomib	C19H25BN4O4	387447	Minor		Inter Info	[157]
D0208		Brivaracetam	C11H20N2O2	9837243	Minor		Inter Info	[4], [167]
	CYP450 enzyme induction					Drug Num: 9
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0044		Alpelisib	C19H22F3N5O2S	56649450	Moderate		Inter Info	[40]
D0578		Enzalutamide	C21H16F4N4O2S	15951529	Moderate		Inter Info	[89], [3], [4], [90]
D0906		Letermovir	C29H28F4N4O4	45138674	Moderate		Inter Info	[113]
D0953		Lorlatinib	C21H19FN6O2	71731823	Moderate		Inter Info	[3], [4], [116]
D0958		Lumacaftor	C24H18F2N2O5	16678941	Moderate		Inter Info	[117], [4], [118]
D1400		Rifampicin	C43H58N4O12	135398735	Moderate		Inter Info	[4], [137], [138]
D1493		Somapacitan	C54H95N13O20S2	129894493	Moderate		Inter Info	[3], [4], [140]
D1502		St. John's Wort	NA	NA	Moderate		Inter Info	[4], [137]
D1494		Somatotropin	NA	NA	Moderate		Inter Info	[3], [4], [140]
	Competitive inhibition of metabolic enzyme					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0120		Atorvastatin	C33H35FN2O5	60823	Moderate		Inter Info	[56], [57], [58]
D0956		Lovastatin	C24H36O5	53232	Moderate		Inter Info	[56], [57], [58]
D1473		Simvastatin	C25H38O5	54454	Moderate		Inter Info	[56], [57], [58]
Affected excretion pathways
	Competitive inhibition of renal tubular secretion					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1025		Methotrexate	C20H22N8O5	126941	Major		Inter Info	[3], [14], [15]
Pharmacodynamic additive effects
	Increased risk of hypomagnesemia					Drug Num: 40
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0306		Cetuximab	NA	NA	Moderate		Inter Info	[27]
D0402		Cyclosporine	C62H111N11O12	5284373	Moderate		Inter Info	[27]
D0056		Amikacin	C22H43N5O13	37768	Moderate		Inter Info	[27]
D0057		Amikacin (liposome)	C22H43N5O13	37768	Moderate		Inter Info	[31], [41], [27]
D0075		Amphotericin B	C47H73NO17	5280965	Moderate		Inter Info	[27]
D0076		Amphotericin B (cholesteryl sulfate)	C47H73NO17	5280965	Moderate		Inter Info	[31], [41], [27]
D0077		Amphotericin B (lipid complex)	C47H73NO17	5280965	Moderate		Inter Info	[31], [41], [27]
D0078		Amphotericin B (liposomal)	C47H73NO17	5280965	Moderate		Inter Info	[31], [41], [27]
D0158		Bendroflumethiazide	C15H14F3N3O4S2	2315	Moderate		Inter Info	[27]
D0166		Benzthiazide	C15H14ClN3O4S3	2343	Moderate		Inter Info	[27]
D0217		Bumetanide	C17H20N2O5S	2471	Moderate		Inter Info	[27]
D0252		Capreomycin	C50H88N28O15	3000502	Moderate		Inter Info	[27]
D0260		Carboplatin	C6H12N2O4Pt	426756	Moderate		Inter Info	[27]
D0321		Chlorothiazide	C7H6ClN3O4S2	2720	Moderate		Inter Info	[27]
D0326		Chlorthalidone	C14H11ClN2O4S	2732	Moderate		Inter Info	[27]
D0344		Cisplatin	Cl2H6N2Pt	5702198	Moderate		Inter Info	[27]
D0613		Etacrynic acid	C13H12Cl2O4	3278	Moderate		Inter Info	[31], [41], [27]
D0694		Foscarnet	CH3O5P	3415	Moderate		Inter Info	[27]
D0704		Furosemide	C12H11ClN2O5S	3440	Moderate		Inter Info	[27]
D0718		Gentamicin	C21H43N5O7	3467	Moderate		Inter Info	[27]
D0771		Hydrochlorothiazide	C7H8ClN3O4S2	3639	Moderate		Inter Info	[27]
D0775		Hydroflumethiazide	C8H8F3N3O4S2	3647	Moderate		Inter Info	[27]
D0798		Indapamide	C16H16ClN3O3S	3702	Moderate		Inter Info	[27]
D0876		Kanamycin	C18H36N4O11	6032	Moderate		Inter Info	[27]
D1048		Metolazone	C16H16ClN3O3S	4170	Moderate		Inter Info	[27]
D1120		Neomycin	C23H46N6O13	8378	Moderate		Inter Info	[27]
D1126		Netilmicin	C21H41N5O7	441306	Moderate		Inter Info	[27]
D1136		Nilotinib	C28H22F3N7O	644241	Moderate		Inter Info	[122]
D1220		Panitumumab	NA	NA	Moderate		Inter Info	[27]
D1228		Paromomycin	C23H45N5O14	165580	Moderate		Inter Info	[27]
D1231		Patiromer	NA	NA	Moderate		Inter Info	[27]
D1246		Pentamidine	C19H24N4O2	4735	Moderate		Inter Info	[27]
D1304		Plazomicin	C25H48N6O10	42613186	Moderate		Inter Info	[27]
D1311		Polythiazide	C11H13ClF3N3O4S3	4870	Moderate		Inter Info	[27]
D1507		Streptomycin	C21H39N7O12	19649	Moderate		Inter Info	[27]
D1526		Tacrolimus	C44H69NO12	445643	Moderate		Inter Info	[3], [4], [141], [142], [143], [144], [145], [146], [147], [148], [29], [30], [31], [32], [33], [149], [34], [150], [151], [27], [152]
D1597		Tobramycin	C18H37N5O9	36294	Moderate		Inter Info	[27]
D1605		Tolevamer	C11H16O3S	58817179	Moderate		Inter Info	[31], [41], [27]
D1611		Torasemide	C16H20N4O3S	41781	Moderate		Inter Info	[31], [41], [27]
D1633		Trichlormethiazide	C8H8Cl3N3O4S2	5560	Moderate		Inter Info	[27]
	Increased risk of photosensitivity reactions					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1314		Porfimer sodium	C68H74N8O11	135577896	Moderate		Inter Info	[125], [4], [126]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0929		Linaclotide	C59H79N15O21S6	16158208	Minor		Inter Info	[169], [170]

References
1	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
2	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
3	Cerner Multum, Inc. "Australian Product Information.".
4	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5	Drug interactions. Atazanavir and acid-reducing agents. TreatmentUpdate 18 (2006): 4. [PMID: 17209238]
6	Product Information. Evotaz (atazanavir-cobicistat). Bristol-Myers Squibb, Princeton, NJ.
7	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
8	Ray JE, Marriott D, Bloch MT, McLachlan AJ "Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic." Br J Clin Pharmacol 60 (2005): 291-9. [PMID: 16120068]
9	Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9. [PMID: 10930147]
10	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
11	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
12	Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52. [PMID: 20716581]
13	Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
14	Breedveld P, Zelcer N, Pluim D, et.al "Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions." Cancer Res 64 (2004): 5804-11.[PMID: 15313923]
15	Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J "Potential interaction between methotrexate and omeprazole/." Ann Pharmacother 34 (2000): 1024-7.[PMID: 10981249]
16	Product Information. Viracept (nelfinavir). Agouron Pharma Inc, La Jolla, CA.
17	Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
18	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
19	Product Information. Votrient (pazopanib). GlaxoSmithKline, Research Triangle Park, NC.
20	Tan AR, Gibbon DG, Stein MN, et al. "Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors." Cancer Chemother Pharmacol 71 (2013): 1635-43. [PMID: 23636448]
21	van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG "Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective." Lancet Oncol 15 (2014): e315-e326. [PMID: 24988935]
22	Yu G, Zheng QS, Wang DX, Zhou HH, Li GF "Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye." Lancet Oncol 15 (2014): e469-70. [PMID: 25281461]
23	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
25	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
26	Product Information. Epclusa (sofosbuvir-velpatasvir). Gilead Sciences, Foster City, CA.
27	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
28	Niwa T, Shiraga T, Takagi A "Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes." Biol Pharm Bull 28 (2005): 1805-8. [PMID: 16141567]
29	Product Information. Aciphex (rabeprazole) Janssen Pharmaceuticals, Titusville, NJ.
30	Product Information. Dexilant (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
31	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
32	Product Information. Prevacid (lansoprazole). TAP Pharmaceuticals Inc, Deerfield, IL.
33	Product Information. Prilosec (omeprazole). Merck & Co, Inc, West Point, PA.
34	Product Information. Protonix (pantoprazole) Wyeth-Ayerst Laboratories, Philadelphia, PA.
35	Zimmermann T, Yeates RA, Riedel KD, Lach P, Laufen H "The influence of gastric ph on the pharmacokinetics of fluconazole: the effect of omeprazole." Int J Clin Pharmacol Ther 32 (1994): 491-6. [PMID: 7820333]
36	Lu C, Berg C, Prakash SR, Lee FW, Balani SK "Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole." Drug Metab Dispos 36 (2008): 1261-6. [PMID: 18381488]
37	Christensen M, Tybring G, Mihara K, et al. "Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)." Clin Pharmacol Ther 71 (2002): 141-52. [PMID: 11907488]
38	Yasui-Furukori N, Takahata T, Nakagami T, et al. "Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes." Br J Clin Pharmacol 57 (2004): 487-94. [PMID: 15025747]
39	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
40	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
41	Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
42	Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
43	Andersson T, HassanAlin M, Hasselgren G, Rohss K "Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole." Clin Pharmacokinet 40 (2001): 523-37. [PMID: 11510629]
44	Product Information. Coumadin (warfarin). DuPont Pharmaceuticals, Wilmington, DE.
45	Product Information. Omeprazole (omeprazole). Mylan Pharmaceuticals Inc, Morgantown, WV.
46	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man." Int J Clin Pharmacol Ther 32 (1994): 385-99. [PMID: 7981922]
47	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man: an updated review." Int J Clin Pharmacol Ther 34 (1 suppl) (1996): s31-50. [PMID: 8793602]
48	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man: an updated review." Int J Clin Pharmacol Ther 34 (1996): 243-62. [PMID: 8793611]
49	Sutfin T, Blamer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O "Stereoselective interaction of omeprazole with warfarin in healthy men." Ther Drug Monit 11 (1989): 176-84. [PMID: 2718223]
50	Unge P, Svedberg LE, Nordgren A, et al. "A study of the interaction of omeprazole and warfarin in anticoagulated patients." Br J Clin Pharmacol 34 (1992): 509-12. [PMID: 1493083]
51	Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]
52	Dequardo JR "Modafinil-associated clozapine toxicity." Am J Psychiatry 159 (2002): 1243-1244. [PMID: 12091210]
53	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
54	Product Information. Provigil (modafinil). Cephalon, Inc, West Chester, PA.
55	Robertson P, Decory HH, Madan A, Parkinson A "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil." Drug Metab Dispos 28 (2000): 664-71. [PMID: 10820139]
56	Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
57	Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF "Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein." Naunyn Schmiedebergs Arch Pharmacol 364 (2001): 551-7. [PMID: 11770010]
58	Sipe BE, Jones RJ, Bokhart GH "Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction." Ann Pharmacother 37 (2003): 808-11. [PMID: 12773066]
59	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
60	Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9. [PMID: 6091711]
61	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
63	Hughes GS, Heald DL, Barker KB, et al. "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther 46 (1989): 674-85. [PMID: 2557183]
64	Saathoff N, Lode H, Neider K, et al "Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist." Antimicrob Agents Chemother 36 (1992): 796-800. [PMID: 1354432]
65	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
66	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
67	Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
68	de Aquino Lima JP, Brophy JM "The potential interaction between clopidogrel and proton pump inhibitors: a systematic review." BMC Med 8 (2010): 81. [PMID: 21134261]
69	Freedman JE, Hylek EM "Clopidogrel, genetics, and drug responsiveness." N Engl J Med 360 (2009): 411-3. [PMID: 19164193]
70	Frere C, Cuisset T, Morange PE, et al. "Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome." Am J Cardiol 101 (2008): 1088-1093. [PMID: 18394438]
71	Hulot JS, Bura A, Villard E, et al. "Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects." Blood (2006):. [PMID: 16772608]
72	Juurlink DN, Gomes T, Ko DT, et al "A population-based study of the drug interaction between proton pump inhibitors and clopidogrel." CMAJ 180 (2009): 713-8. [PMID: 19176635]
73	Lau WC, Gurbel PA "The drug-drug interaction between proton pump inhibitors and clopidogrel." CMAJ 180 (2009): 699-700. [PMID: 19332744]
74	Li XQ, Andersson TB, Ahlstrom M, Weidolf L "Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities." Drug Metab Dispos 32 (2004): 821-7. [PMID: 15258107]
75	Mega JL, Close SL, Wiviott SD, et al. "Cytochrome p-450 polymorphisms and response to clopidogrel." N Engl J Med 360 (2009): 354-62. [PMID: 19106084]
76	Moayyedi P, Sadowski DC "Proton pump inhibitors and clopidogrel -- hazardous drug interaction or hazardous interpretation of data?" Can J Gastroenterol 23 (2009): 251-2. [PMID: 19373416]
77	Pezalla E, Day D, Pulliadath I "Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors." J Am Coll Cardiol 52 (2008): 1038-9. [PMID: 18786491]
78	Simon T, Verstuyft C, Mary-Krause M, et al "Genetic determinants of response to clopidogrel and cardiovascular events." N Engl J Med 360 (2009): 363-75. [PMID: 19106083]
79	Small DS, Farid NA, Payne CD, et al. "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel." J Clin Pharmacol 48 (2008): 475-84. [PMID: 18303127]
80	Varenhorst C, Janes S, Erlinge D, et al "Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease." Eur Heart J 30 (2009): 1744-52. [PMID: 19429918]
81	EMA. European Medicines Agency "Interaction between clopidogrel and proton-pump inhibitors.".
82	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
83	Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
84	Kiley CA, Cragin DJ, Roth BJ "Omeprazole-associated digoxin toxicity." South Med J 100 (2007): 400-2. [PMID: 17458401]
85	Le GH, Schaefer MG, Plowman BK, et al. "Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors." Am J Health Syst Pharm 60 (2003): 1343-5. [PMID: 12901036]
86	Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN "Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose." Br J Clin Pharmacol 32 (1991): 569-72. [PMID: 1954072]
87	Product Information. Kapidex (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
88	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
89	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
90	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
91	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
92	Product Information. Inrebic (fedratinib). Celgene Corporation, Summit, NJ.
93	Product Information. Antara (fenofibrate). Lupin Pharmaceuticals Inc, Baltimore, MD.
94	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
95	Nand S, Tanvetyanon T "Proton pump inhibitors and iron deficiency: is the connection real?" South Med J 97 (2004): 799. [PMID: 15455957]
96	Sharma VR, Brannon MA, Carloss EA "Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia." South Med J 97 (2004): 887-9. [PMID: 15455980]
97	Stewart CA, Termanini B, Sutliff VE, et al "Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy." Aliment Pharmacol Ther 12 (1998): 83-98. [PMID: 9692706]
98	Product Information. Prilosec (omeprazole). Merck &amp Co, Inc, West Point, PA.
99	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
100	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
101	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
102	Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
103	Product Information. Ravicti (glycerol phenylbutyrate). Hyperion Therapeutics Inc, South San Francisco, CA.
104	Burger DM, Hugen PWH, Kroon FP, Groeneveld P, Brinkman K, Foudraine NA, Sprenger H, Koopmans PP, Hekster YA "Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir." AIDS 12 (1998): 2080-2. [PMID: 9814882]
105	Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
106	Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6. [PMID: 6310994]
107	Chin TWF, Loeb M, Fong IW "Effects of an acidic beverage (coca-cola) on absorption of ketoconazole." Antimicrob Agents Chemother 39 (1995): 1671-5. [PMID: 7486898]
108	Jaruratanasirikul S, Sriwiriyajan S "Effect of omeprazole on the pharmacokinetics of itraconazole." Eur J Clin Pharmacol 54 (1998): 159-61. [PMID: 9626921]
109	Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ "Effects of ranitidine and sucralfate on ketoconazole bioavailability." Antimicrob Agents Chemother 35 (1991): 1765-71. [PMID: 1952845]
110	Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4. [PMID: 6253434]
111	Product Information. Vitrakvi (larotrectinib). Bayer Pharmaceutical Inc, West Haven, CT.
112	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
113	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
114	Product Information. Synthroid (levothyroxine). Abbott Pharmaceutical, Abbott Park, IL.
115	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
116	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
117	Cerner Multum, Inc. "Canadian Product Information.".
118	Product Information. Orkambi (ivacaftor-lumacaftor). Vertex Pharmaceuticals, Cambridge, MA.
119	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
120	Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
121	Product Information. Naprosyn (naproxen). Syntex Laboratories Inc, Palo Alto, CA.
122	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
123	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
124	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
125	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
126	Product Information. Photofrin (porfimer). Sanofi Winthrop Pharmaceuticals, New York, NY.
127	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
128	Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ "Multicenter study of posaconazole therapeutic drug monitoring: exposure-response and factors affecting concentration." Antimicrob Agents Chemother 56 (2012): 5503-10. [PMID: 22890761]
129	Krishna G, Abutarif M, Xuan F, Martinho M, Angulo D, Cornely OA "Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome." Pharmacotherapy 28 (2008): 1223-32. [PMID: 18823218]
130	Krishna G, Moton A, Ma L, Medlock MM, McLeod J "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers." Antimicrob Agents Chemother 53 (2009): 958-66. [PMID: 19075045]
131	Neubauer WC, Engelhardt M, Konig A, et al. "Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method." Antimicrob Agents Chemother 54 (2010): 4029-32. [PMID: 20547790]
132	Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
133	Shields RK, Clancy CJ, Vadnerkar A, et al "Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy." Antimicrob Agents Chemother 55 (2011): 1308-11. [PMID: 21189337]
134	Vaes M, Hites M, Cotton F, et al. "Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome." Antimicrob Agents Chemother 56 (2012): 6298-303. [PMID: 23027198]
135	Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34. [PMID: 21973269]
136	Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20.
137	Product Information. Rifadin (rifampin). Hoechst Marion-Roussel Inc, Kansas City, MO.
138	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
139	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
140	Product Information. Zorbtive (somatropin). Serono Laboratories Inc, Rockland, MA.
141	Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T "Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19." Clin Pharmacol Ther 70 (2001): 484-92. [PMID: 11719736]
142	Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y "Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with cyp2c19 gene mutation." Transplantation 73 (2002): 303-4. [PMID: 11821750]
143	Itagaki F, Homma M, Yuzawa K, et al "Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations." J Pharm Pharmacol 56 (2004): 1055-9. [PMID: 15285851]
144	Itagaki F, Homma M, Yuzawa K, Fukao K, Kohda Y "Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation." Transplant Proc 34 (2002): 2777-8. [PMID: 12431607]
145	Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y "Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: Consequences for FK506 assimilation." Kidney Int 67 (2005): 1152-60. [PMID: 15698457]
146	Lorf T, Ramadori G, Ringe B, Schworer H "The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients." Eur J Clin Pharmacol 56 (2000): 439-40. [PMID: 11009056]
147	Miura M, Inoue K, Kagaya H, et al. "Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients." Biopharm Drug Dispos 28 (2007): 167-75. [PMID: 17377957]
148	Pascual J, Marcen R, Orea OE, et al. "Interaction Between Omeprazole and Tacrolimus in Renal Allograft Recipients: A Clinical-Analytical Study." Transplant Proc 37 (2005): 3752-3753. [PMID: 16386527]
149	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
150	Schwrer H, Lorf T, Ringe B, Ramadori G "Pantoprazole and cyclosporine or tacrolimus." Aliment Pharmacol Ther 15 (2001): 561-2. [PMID: 11284790]
151	Takahashi K, Motohashi H, Yonezawa A, et al "Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism." Ann Pharmacother 38 (2004): 791-4. [PMID: 15010519]
152	Iwamoto T, Monma F, Fujieda A, Nakatani K, Katayama N, Okuda M "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations." Clin Ther 33 (2011): 1077-80. [PMID: 21802143]
153	Eiden C, Peyriere H, Tichit R, et al. "Inherited long QT syndrome revealed by antifungals drug-drug interaction." J Clin Pharm Ther 32 (2007): 321-4. [PMID: 17489884]
154	Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O "Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes." Clin Infect Dis 46 (2008): 201-11. [PMID: 18171251]
155	Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
156	Wood N, Tan K, Purkins L, et al. "Effect of omeprazole on the steady-state pharmacokinetics of voriconazole." Br J Clin Pharmacol 56 Suppl 1 (2003): 56-61. [PMID: 14616415]
157	Product Information. Velcade (bortezomib). Millennium Pharmaceuticals Inc, Cambridge, MA.
158	Bradford GS, Taylor CT "Omeprazole and vitamin B-12 deficiency." Ann Pharmacother 33 (1999): 641-3. [PMID: 10369631]
159	Dutta SK "Vitamin b-12 malabsorption and omeprazole therapy." J Am Coll Nutr 13 (1994): 544-5. [PMID: 7706583]
160	Lavy NW "Omeprazole and vitamin B12." Ann Intern Med 121 (1994): 74. [PMID: 8198354]
161	Marcuard SP, Albernaz L, Khazanie PG "Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin-b12)." Ann Intern Med 120 (1994): 211-5. [PMID: 8273984]
162	Salom IL, Silvis SE, Doscherholmen A "Effect of cimetidine on the absorption of vitamin B12." Scand J Gastroenterol 17 (1982): 129-31. [PMID: 7134827]
163	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
164	Inarrea P, Esteva F, Cornudella R, Lanas A "Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man." Scand J Gastroenterol 35 (2000): 242-6. [PMID: 10766315]
165	Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N "Interaction of omeprazole with enteric-coated salicylate tablets." Int J Clin Pharmacol Ther 36 (1998): 549-53. [PMID: 9799060]
166	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
167	Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
168	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
169	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
170	Product Information. Linzess (linaclotide). Forest Pharmaceuticals, St. Louis, MO.
171	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
172	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
173	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
174	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
175	Product Information. Erivedge (vismodegib). Genentech, South San Francisco, CA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence